TDO2 and ovarian serous adenocarcinoma: Our findings demonstrate enhanced amino acid metabolism by IDO1/TDO and IL4I1 in high-grade serous ovarian cancer patients, with markedly elevated metabolite levels in patient ascites samples compared to patient and healthy donor plasma.